Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00161668 |
This study is designed to assess the safety of Mylotarg therapy in routine practice.
Condition | Intervention | Phase |
---|---|---|
Acute Myeloid Leukemia |
Drug: Mylotarg |
Phase IV |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
Official Title: | Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: - Treated by Mylotarg - Provide ICF
Study Director: | Medical Monitor | Wyeth |
Study ID Numbers: | 0903X-100847 |
Study First Received: | September 8, 2005 |
Last Updated: | March 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00161668 History of Changes |
Health Authority: | United States: Institutional Review Board |
Leukemia |
Leukemia Acute Myelocytic Leukemia Leukemia, Myeloid Gemtuzumab Leukemia, Myeloid, Acute |
Leukemia Neoplasms Neoplasms by Histologic Type Antineoplastic Agents Therapeutic Uses |
Leukemia, Myeloid Gemtuzumab Leukemia, Myeloid, Acute Pharmacologic Actions |